MDM2 and cancer: The ability of ALRN-6924 to block MDM2 and MDMX, thereby restoring p53 activity, offers a potent therapeutic strategy, particularly for cancers that retain functional p53 but are suppressed by overactive MDM2/MDMX interactions.